Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
GHK-Cu is not approved by the FDA or any regulatory agency for therapeutic or cosmetic use
High Expenditure and Supply Chain Issues: Major Limitations In the global GLP-1 receptor agonist market, arising challenges are the high expenses of these drugs, which pose a hurdle for many patients
doi: 10.1126/sciimmunol.aay0555 157 ZhuLYuXWangLLiuJQuZZhangHet al
Clinical trial protocols from the Phase 2 NEJM study used a gradual escalation approach, starting at low doses and increasing every four weeks
US$ 24.89
US$ 23.24
US$ 23.87
US$ 27.52
US$ 29.58
